Management of Symptomatic Neurogenic Orthostatic Hypotension

Non‑Pharmacological Measures

• Eliminate drugs that can lower blood pressure (e.g., diuretics, vasodilators, psychotropic agents, α‑adrenoreceptor antagonists) because medication‑induced hypotension is the most common reversible cause. 1
• Restore intravascular volume in patients with acute dehydration using oral or intravenous fluid replacement. 2
• Apply physical counter‑measures such as leg crossing, squatting, or lower‑body muscle tensing to raise blood pressure through isometric contraction. 1
• Use thigh‑high (preferably abdominal‑including) compression garments to lessen orthostatic symptoms. 1
• Ingest 240–480 mL of water acutely; the pressor effect peaks at about 30 minutes and provides temporary symptom relief. 1

First‑Line Pharmacologic Therapy

Midodrine (Class I recommendation, strongest evidence)

• Midodrine is the primary first‑line agent for symptomatic orthostatic hypotension and is the only FDA‑approved medication for this indication. 1
• Mechanism: selective peripheral α₁‑adrenergic agonism producing arteriolar and venous constriction. 3
• Dosing: titrate up to 10 mg 2–4 times daily, with the first dose taken before arising. 3
• Efficacy: produces a dose‑dependent increase in standing blood pressure and improves symptoms. 1
• Major adverse effect: supine hypertension (the principal limiting factor), plus scalp tingling, piloerection, urinary retention, and bradycardia. 1
• Practical caveat: avoid dosing within several hours of planned recumbency, especially in patients with documented supine hypertension. 3

Droxidopa (Class IIa recommendation)

• Droxidopa is considered equally effective to midodrine for neurogenic orthostatic hypotension. 1
• Mechanism: a norepinephrine precursor that raises circulating norepinephrine levels; useful in Parkinson disease, pure autonomic failure, and multiple system atrophy. 1
• Potential benefit: small studies suggest a reduction in falls. 1
• Interaction: concurrent carbidopa therapy may diminish droxidopa’s effectiveness. 1
• Adverse effects: supine hypertension, headache, dizziness, and nausea. 1

Second‑Line Pharmacologic Options

Fludrocortisone

• Considered after midodrine or droxidopa because of concerns about long‑term safety. 1
• Mechanism: increases plasma volume via sodium retention, adds direct vascular constriction, and reduces vessel wall distensibility. 3
• Dosing: initiate 0.05–0.1 mg daily; titrate to a maximum of 0.1–0.3 mg daily. 3
• When supine hypertension is present, other agents should be tried before fludrocortisone. 1
• Serious adverse effects at doses >0.3 mg daily include adrenal suppression, immunosuppression, edema, hypokalemia, and precipitating congestive heart failure. 1

Salt and Fluid Supplementation

• Increasing dietary salt (≈6–9 g/day, ~1–2 teaspoons) and fluid intake may be reasonable in selected patients without contraindications. 1
• Contraindications: existing hypertension, renal impairment, heart failure, or other cardiac dysfunction. 1
• Limited additional benefit in individuals already consuming high amounts of salt. 4

Agents for Refractory Cases

Pyridostigmine (Class IIb recommendation)

• May be useful when first‑line agents fail. 4
• Mechanism: enhances orthostatic tolerance by increasing peripheral vascular resistance. 4
• Adverse effects: nausea, vomiting, abdominal cramping, sweating, excessive salivation, and urinary incontinence. 4

Octreotide

• Considered for refractory post‑prandial or neurogenic orthostatic hypotension. 4
• Mechanism: reduces splanchnic blood flow by roughly 20 %, thereby mitigating post‑prandial blood pressure drops. 4

Management Principles & Common Pitfalls

• The therapeutic goal is to lessen postural symptoms and improve quality of life rather than to normalize blood pressure. 3
• The principal challenge is achieving sufficient standing blood pressure improvement while avoiding marked supine hypertension. 3
• Pitfall 1: Do not use fludrocortisone as first‑line therapy when supine hypertension is present. 1
• Pitfall 2: Do not administer midodrine shortly before planned recumbency because of the risk of supine hypertension. 3
• Pitfall 3: Do not add salt or fluid supplementation in patients with hypertension, renal disease, or heart failure. 1
• Pitfall 4: Always review the patient’s medication list; drug‑induced hypotension is the most common reversible cause. 1

Off‑Label Pharmacologic Management of Orthostatic Hypotension

Fludrocortisone (Mineralocorticoid)

• The American College of Cardiology gives a Class IIa recommendation with Level B evidence for fludrocortisone in neurogenic orthostatic hypotension, recommending initiation at 0.05–0.1 mg once daily and titration up to a maximum of 0.1–0.3 mg daily based on symptom response【5】.
• Fludrocortisone should not be used as first‑line therapy when supine hypertension is present, and doses > 0.3 mg/day markedly increase the risk of adrenal suppression, immunosuppression, peripheral edema, hypokalemia, congestive heart‑failure decompensation, and higher all‑cause hospitalization rates【5】.
• Required monitoring includes regular supine blood‑pressure checks, serum potassium assessment, evaluation for fluid overload, and cardiac‑function surveillance, especially in patients with existing cardiac disease or restrictive physiology【5】.

Pyridostigmine (Acetylcholinesterase Inhibitor)

• The American College of Cardiology assigns a Class IIb recommendation with Level C evidence for pyridostigmine in refractory neurogenic orthostatic hypotension, to be used after failure of first‑line agents (midodrine, droxidopa) and fludrocortisone【5】.
• Pyridostigmine provides symptomatic improvement without causing fluid retention or supine hypertension, making it better tolerated in patients with heart‑failure‑related concerns【5】.
• It is most effective in individuals with relatively preserved sympathetic reserve (e.g., multiple system atrophy with normal or mildly reduced plasma norepinephrine)【5】.
• Common adverse effects are cholinergic (nausea, vomiting, abdominal cramping, excessive sweating, salivation, urinary incontinence) and require clinical monitoring rather than laboratory testing【5】.

Octreotide (Somatostatin Analog)

• The American College of Cardiology provides a Class IIb recommendation with Level C evidence for octreotide in patients with refractory post‑prandial or neurogenic orthostatic hypotension after other agents have failed【5】.
• Its mechanism reduces splanchnic blood flow by ≈ 20 %, attenuating post‑meal blood‑pressure drops【5】.
• Administration is subcutaneous with individualized dosing based on clinical response; monitoring focuses on gastrointestinal side effects, glucose abnormalities, and efficacy against post‑prandial hypotension【5】.

Salt and Fluid Supplementation (Adjunct)

• The American College of Cardiology gives a Class IIb recommendation with Level C evidence for targeted salt and fluid augmentation in selected orthostatic‑hypotension patients【5】.
• Suggested regimen: ≈ 6–9 g of dietary salt per day (1–2 tsp) and 2–3 L of fluid daily; however, this is contraindicated in patients with existing hypertension, renal impairment, or heart failure due to risk of volume overload【5】.

Monitoring Priorities Across Off‑Label Therapies

• Supine hypertension is the principal limiting factor for all pressor agents (fludrocortisone, midodrine, droxidopa) and must be checked regularly【5】.
• Serum potassium should be monitored when fludrocortisone is used because of the risk of hypokalemia【5】.
• Cardiac function assessment is essential when using volume‑expanding agents (fludrocortisone, salt/fluid supplementation) to detect early fluid overload or heart‑failure exacerbation【5】.

Suggested Treatment Algorithm (Off‑Label)